Zhongyu Lu

State Key Laboratory Of Neurology And Oncology Drug Development
Nanjing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

xinguangA preliminary characterization of PI4K/PIPK alterations across solid tumors: an exploratory framework for prognostic and therapeutic stratification.

xinguangA preliminary characterization of PI4K/PIPK alterations across solid tumors: an exploratory framework for prognostic and therapeutic stratification.

Journal: Cancer biology & therapy

Published: July 14, 2026

Integrated Genomic and Immune Profiling of Early Onset Lung Cancer in East Asians Reveals a Distinct Molecular Architecture.

Integrated Genomic and Immune Profiling of Early Onset Lung Cancer in East Asians Reveals a Distinct Molecular Architecture.

Journal: Clinical lung cancer

Published: April 28, 2026

Global Dual Incidence-Mortality Patterns of Prostate Cancer Across SDI Regions, 1990-2021: A Cross-Sectional Study Based on Global Burden of Disease 2021.

Global Dual Incidence-Mortality Patterns of Prostate Cancer Across SDI Regions, 1990-2021: A Cross-Sectional Study Based on Global Burden of Disease 2021.

Journal: Health science reports

Published: January 12, 2026

Tislelizumab and hypofractionated radiotherapy plus nab-paclitaxel/gemcitabine as conversion therapy for BRPC/LAPC: A Phase II trial with dynamic biomarker monitoring.

Tislelizumab and hypofractionated radiotherapy plus nab-paclitaxel/gemcitabine as conversion therapy for BRPC/LAPC: A Phase II trial with dynamic biomarker monitoring.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 02, 2025

ALAD as a prognostic biomarker regulates metabolism and immune responses in renal cell carcinoma through multi-omics analysis.

ALAD as a prognostic biomarker regulates metabolism and immune responses in renal cell carcinoma through multi-omics analysis.

Journal: Translational oncology

Published: March 10, 2025

Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer.

Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer.

Journal: Cancer biology & therapy

Published: September 21, 2024

Development and validation of a prognostic and drug sensitivity model for gastric cancer utilizing telomere-related genes.

Development and validation of a prognostic and drug sensitivity model for gastric cancer utilizing telomere-related genes.

Journal: Translational oncology

Published: July 29, 2024

Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study.

Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 19, 2024

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib.

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib.

Journal: Lung Cancer (Auckland, N.Z.)

Published: July 20, 2023

Partial Response to Crizotinib in a Lung Adenocarcinoma Patient with a Novel FBXO11 (Intergenic)-ALK (Exon 20-29) Fusion.

Partial Response to Crizotinib in a Lung Adenocarcinoma Patient with a Novel FBXO11 (Intergenic)-ALK (Exon 20-29) Fusion.

Journal: OncoTargets and therapy

Published: January 29, 2023

Showing 1-10 of 10

Last Updated: 09/26/2026